source
- Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseasesPfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…
- AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeuticsAbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…